ESMO TAT 2023 | SRK-181 as a novel latent TGFβ1 selective inhibitor

Timothy Yap, MBBS, PhD, FRCP, The University of Texas MD Anderson Cancer Center, Houston, TX, outlines the characteristics and emerging data pertaining to SRK-181, a latent TGFβ1 selective isoform inhibitor. Properties such as its selectivity, preference to target TGFβ1’s latent form, and its ability to target all sources of TGFβ1, set it apart from similar agents. The Phase I of the DRAGON trial (NCT04291079) has observed that SRK-181 is tolerated as a monotherapy, and in combination with anti-PD-1 or PD-L1 inhibitors at all doses. Notably, the trial has recorded 3 durable partial responses in patients with cases of clear cell renal rell carcinoma (ccRCC) that are resistant to anti–PD-1 treatments. This interview took place at the ESMO Targeted Anticancer Therapies (TAT) Congress 2023 in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.